A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB.

导出 OA

翻译打印收藏纠错

作者： Giuseppe,Tringali ^[1] ; Catello,Vollono ^[2] ; Paolo,Calabresi ^[3] ; Pierluigi,Navarra ^[3]

作者单位： Department of Healthcare Surveillance and Bioethics, Section of Pharmacology, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168, Rome, Italy. ^[1] Neurofisiopatologia - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. ^[2] Neurologia - Università Cattolica del Sacro Cuore, Rome, Italy. ^[3] Neurologia - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. ^[4] Department of Healthcare Surveillance and Bioethics, Section of Pharmacology, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168, Rome, Italy. pierluigi.navarra@unicatt.it. ^[5] Pharmacology - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. pierluigi.navarra@unicatt.it. ^[6]

关键词 CGRP CGRP receptor Erenumab Migraine Monoclonal antibodies

DOI 10.1186/s10194-020-01193-4

PMID 33087040

发布时间 2020-12-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交